This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pereira-Chioccola, V. L.
Right arrow Articles by Schenkman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pereira-Chioccola, V. L.
Right arrow Articles by Schenkman, S.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 826-830, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.826-830.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Enzyme-Linked Immunoassay Using Recombinant trans-Sialidase of Trypanosoma cruzi Can Be Employed for Monitoring of Patients with Chagas' Disease after Drug Treatment

Vera Lucia Pereira-Chioccola,1* Abilio Augusto Fragata-Filho,2 Antonio Marcos de Apparecida Levy,2 Mauricio M. Rodrigues,3 and Sergio Schenkman3

Laboratório de Parasitologia, Instituto Adolfo Lutz,1 Laboratório de Xenodiagnóstico, Instituto Dante Pazzanese de Cardiologia,2 Departamento de Microbiologia, Imunologia e Parasitologia, UNIFESP, São Paulo, SP, Brazil3

Received 24 March 2003/ Returned for modification 1 May 2003/ Accepted 8 July 2003

trans-Sialidase is an enzyme present on the surface of Trypanosoma cruzi and is an important antigen recognized by sera from patients with Chagas' disease. In the present study we investigated whether the benznidazole treatment of patients with Chagas' disease induced changes in the reactivity of serum toward a recombinant form of trans-sialidase in order to develop an assay for monitoring of patients after treatment for Chagas' disease, which is needed at Chagas' disease control centers. By using an enzyme-linked immunosorbent assay containing a recombinant protein corresponding to the catalytic domain of trans-sialidase, we found that the antigen had a high specificity for sera from untreated patients with Chagas' disease. Sera from healthy individuals or patients with active visceral leishmaniasis minimally cross-reacted with the antigen. Anti-trans-sialidase immunoglobulin was detected in 98% of 151 untreated patients with Chagas' disease. Of these, 124 patients were treated for 60 days with benznidazole (5 mg/kg of body weight/day), and their sera were assayed for reactivity with the recombinant trans-sialidase. By using this methodology, three groups of patients could be established. The first group (60 patients), which was considered to have been successfully treated, showed no reactivity after treatment. The second group (46 patients) still showed signs of infection, and after treatment their sera recognized trans-sialidase, but with reduced titers. The third group (18 patients) was considered to be resistant to drug treatment, and their sera presented identical reactivities before and after treatment. These results suggest that determination of the absence of antibodies to recombinant trans-sialidase in treated patients by the present assay is indicative of treatment success, while the presence of antibodies may indicate the persistence of infection. Therefore, this method may be useful for the diagnosis and monitoring of patients undergoing benznidazole treatment.

* Corresponding author. Mailing address: Departamento de Parasitologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 355 8° andar, CEP 01246-902, São Paulo, SP, Brazil. Phone: (55 11) 3068 2889. Fax: 55 11 3085 3505. E-mail: pchioccola{at}ial.sp.gov.br.

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 826-830, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.826-830.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Garcia, S., Ramos, C. O., Senra, J. F. V., Vilas-Boas, F., Rodrigues, M. M., Campos-de-Carvalho, A. C., Ribeiro-dos-Santos, R., Soares, M. B. P. (2005). Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations. Antimicrob. Agents Chemother. 49: 1521-1528 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»